At a glance
ClinicalIndex Comparison RecordN/ACompleted· 500 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
New Biomarkers in Heart- and Renal Failure: Cohort Study for Assessing Prognosis in Acute Coronary Syndrome and Acute/Chronic Cardiovascular and Renal Failure by Means of Fibroblast Growth Factor 23
In Brief
An observational study for Heart Failure and Kidney Failure. Completed, enrolled 500 participants across 1 site.
Detailed Summary
In this study, prognostically relevant biomarkers for cardiovascular / renal insufficiencies will be clinically evaluated, to improve the course of assessment of such disease and to gain new insights into the typical course of congestive heart failure. This is a prerequisite to allow patients to appropriate treatment as soon as possible.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Kidney Failure
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartAug 2016
Primary CompletionApr 2018
Study CompletionJun 2018
TodayJul 2026
First PostedJul 12, 2016
Enrollment StartAug 1, 2016
Primary CompletionApr 1, 2018
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.0 years ago